Comparison of bevacizumab (Avastin) and ranibizumab (Lucentis) in exudative age-related macular degeneration.

Completed

• Conditions: eye; retina; age-related macular degeneration; choroidal neovascularization; angiogenesis; bevacizumab; ranibizumab; oog; leeftijdsgebonden maculadegeneratie; Lucentis

• Registration Number: NL-OMON21233
• Lead Sponsor: Prof. Dr. R.O. SchlingemannDepartment of Ophthalmology, Room A2-122Academisch Medisch CentrumMeibergdreef 91105 AZ AmsterdamTel +31205663616e-mail: r.schlingemann@amc.uva.nl

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 306

Inclusion Criteria

1. Patients 60 years of age or higher;

2. Patients with primary or recurrent sub-, juxta- or extrafoveal CNV secondary to AMD, including those with RAP, that may benefit from anti-VEGF treatment in the opinion of the investigator;

Exclusion Criteria

1. Ocular treatment with anti-angiogenic drugs in the last 2 months or Triamcinolone in the last 6 months;

2. Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding Baseline;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome is the change in best-corrected visual acuity (BCVA) in the study eye from Baseline to Month 12 assessed with ETDRS-like VA charts at an initial distance of four meter.